Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States

This article has been corrected. See J Manag Care Spec Pharmacy. 2018;24(7):714. BACKGROUND: New 3-drug regimens have been developed and approved to treat multiple myeloma (MM). The absence of direct comparative data and the high cost of treatment support the need to assess the relative clinical and...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlson, Josh J., Guzauskas, Gregory F., Chapman, Richard H., Synnott, Patricia G., Liu, Shanshan, Russo, Elizabeth T., Pearson, Steven D., Brouwer, Elizabeth D., Ollendorf, Daniel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398323/
https://www.ncbi.nlm.nih.gov/pubmed/29290170
http://dx.doi.org/10.18553/jmcp.2018.24.1.29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398323/
https://www.ncbi.nlm.nih.gov/pubmed/29290170
http://dx.doi.org/10.18553/jmcp.2018.24.1.29

Ejemplares similares